TGTX
TG Therapeutics Inc
Halal Rating :
Last Price
$29.53
Last updated:
Market Cap
-
7D Change
6.72%
1 Year Change
82.06%
Company Overview
Industries
Exchange
Next Earnings Date
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, including chronic lymphocytic leukemia, multiple sclerosis, and other B-cell mediated autoimmune diseases. The company's key product is BRIUMVI (ublituximab), which has received FDA approval for treating relapsing forms of multiple sclerosis.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $83.88m | $82.28m | - | $10.83m | 0.00% | 13.17% |
| June 30, 2024 | $73.47m | $68.63m | - | $3.98m | 0.00% | 5.80% |
| March 31, 2024 | $63.47m | $75.03m | - | $2.29m | 0.00% | 3.05% |
Company Impact
Help us evaluate TG Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.